Stock Info Nets

Independent Financial Information Made Easy

December 22, 2025 5:34 (London Time)

Amgen

Youtube Subscribe

...

Sector: Biotechnology
Ticker: AMGN
Sentiment: 0.5994
MarketCap: 131.22B
High: 331.5 Low: 324.73

Open: 325.56 Close: 327.38 Change: 1.82

How to get informed about Amgen quickly using an AI.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, recently, …

Concept Map

...

Semantic Network

...

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen most recently raised its dividend at the end of 2024, to $2.38 a share. FDA approves Amgens Uplizna for generalized myasthenia gravis.

Today's News

Amgen most recently raised its dividend at the end of 2024, to $2.38 a share. FDA approves Amgens Uplizna for generalized myasthenia gravis.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, recently, raise, dividend, end, share, FDA, and the most common words in the summary are: amgen, news, fda, release, uplizna, generalize, myasthenia, . One of the sentences in the summary was: Amgen most recently raised its dividend at the end of 2024, to $2.38 a share. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #news #fda #release #uplizna #generalize #myasthenia.

Read more →

Related Results

...
December 25, 2025 2:32 (London Time)

Amgen

FDA approves Amgens uplizna for generalized myasthenia gravis with positive achr or musk antibodies. Amgen Inc. (NASDAQ:AMGN) Nasdaq Index Biotechno…
Sector: Biotechnology
Ticker: AMGN
Sentiment: 0.743
MarketCap: 131.22B
High: 334.38 Low: 330.72

Open: 330.72 Close: 333.96 Change: 3.24

Read more →
...
December 23, 2025 3:07 (London Time)

Amgen

FDA approves expansion of Amgens autoimmune therapy Uplizna. Amgen scores uplizna expansion into generalized myasthenia gravis.
Sector: Biotechnology
Ticker: AMGN
Sentiment: 0.4019
MarketCap: 131.22B
High: 331.88 Low: 326.08

Open: 327.01 Close: 331.39 Change: 4.38

Read more →
...
December 22, 2025 5:34 (London Time)

Amgen

Amgen most recently raised its dividend at the end of 2024, to $2.38 a share. FDA approves Amgens Uplizna for generalized myasthenia gravis.
Sector: Biotechnology
Ticker: AMGN
Sentiment: 0.5994
MarketCap: 131.22B
High: 331.5 Low: 324.73

Open: 325.56 Close: 327.38 Change: 1.82

Read more →
...
December 24, 2025 7:19 (London Time)

Amgen

FDA approves Amgens uplizna for generalized myasthenia gravis with positive achr or musk antibodies. Amgen Inc. (NASDAQ:AMGN) Nasdaq Index Biotechno…
Sector: Biotechnology
Ticker: AMGN
Sentiment: 0.743
MarketCap: 131.22B
High: 333.67 Low: 328.07

Open: 328.09 Close: 331.49 Change: 3.4

Read more →
...
December 22, 2025 15:02 (London Time)

Amgen

Amgen most recently raised its dividend at the end of 2024, to $2.38 a share. FDA approves Amgens uplizna for generalized myasthenia gravis.
Sector: Biotechnology
Ticker: AMGN
Sentiment: 0.5994
MarketCap: 131.22B
High: 331.5 Low: 324.73

Open: 325.56 Close: 327.38 Change: 1.82

Read more →